Furthermore, a phase I clinical trial of ROR1-CAR-T cell therapy was initiated to study the side effects and optimal dose in ROR1-positive cancers including stage IV breast cancers and metastatic TNBC (NCT02706392). The gene discussed is ROR1; the disease is breast carcinoma.